ArticleJournal of surgical case reports2026
Curative resection of borderline resectable perihilar cholangiocarcinoma following neoadjuvant gemcitabine and cisplatin plus durvalumab immunochemotherapy: a case report.
Article in Journal of surgical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Postoperative survival benefits of neoadjuvant gemcitabine and cisplatin plus durvalumab (GCD) immunochemotherapy for biliary tract cancers, which meet the criteria for borderline resectability, remain limited. A 75-year-old male presented to our hospital with epigastric pain. Diagnostic imaging demonstrated perihilar cholangiocarcinoma invading the right hepatic artery with lymph node metastasis. The patient was diagnosed with borderline resectable perihilar cholangiocarcinoma (cT3N1M0 Stage IIIC) and treated with seven cycles of GCD immunochemotherapy. Dynamic computed tomography post-immunochemotherapy revealed that the tumor decreased in size, and arterial invasion and swollen lymph nodes had disappeared. At 6 months following immunochemotherapy initiation, the patient underwent left hepatectomy, lymph node dissection, and biliary reconstruction. Histopathology showed inflammatory cell infiltration in the bile duct mucosa without cancer cells. No lymph node metastases were detected. At 2 years postoperatively, the patient remains stable without recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.